Pulmonx Corp. (LUNG) News
Filter LUNG News Items
LUNG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LUNG News From Around the Web
Below are the latest news stories about PULMONX CORP that investors may wish to consider to help them evaluate LUNG as an investment opportunity.
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare ConferenceREDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://inv |
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and ProvidersREDWOOD CITY, Calif., November 19, 2024--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and emphysema. |
Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumREDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic ob |
Pulmonx to Present at the Stifel 2024 Healthcare ConferenceREDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.c |
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Here's What Analysts Are Forecasting For Pulmonx Corporation (NASDAQ:LUNG) After Its Third-Quarter ResultsIt's been a good week for Pulmonx Corporation ( NASDAQ:LUNG ) shareholders, because the company has just released its... |
Pulmonx Third Quarter 2024 Earnings: EPS Beats ExpectationsPulmonx ( NASDAQ:LUNG ) Third Quarter 2024 Results Key Financial Results Revenue: US$20.4m (up 15% from 3Q 2023). Net... |
Pulmonx Corp (LUNG) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...Pulmonx Corp (LUNG) reports a 15% revenue increase, while navigating strategic challenges and opportunities in international markets. |
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue EstimatesPulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |